STOCKWATCH: EU conditional approvals – what gives?
This article was originally published in Scrip
Executive Summary
The adjectives used to describe PTC Therapeutics' conditional European approval for its drug Translarna (ataluren) for Duchenne muscular dystrophy ranged from 'surprise' to 'historic' and helped to bolster PTC's share price by 30% by the close of the day of the announcement (scripintelligence.com, 23 May 2014). PTC's regulatory success was certainly unexpected as it followed a previous rejection by CHMP which cited limited evidence of Translarna's efficacy (scripintelligence.com, 24 January 2014).
You may also be interested in...
Stock Watch: Defeat Is The Mother Of Reinvention
Companies that are successful do not need to change their name, therapeutic area or product focus.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.